Art

J-GLOBAL ID：201702287599759323   Reference number：17A1189579

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

結核処理のための高用量リファンピシン,モキシフロキサシン,およびSQ109:マルチアーム,多段階無作為化対照試験【Powered by NICT】

Author (34)： Boeree Martin J (Department of Lung Diseases, Radboud University Medical Center, Nijmegen, Netherlands) ,  Heinrich Norbert (Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany) ,  Heinrich Norbert (German Center for Infection Research, Partner Site Munich, Germany) ,  Aarnoutse Rob (Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands) ,  Diacon Andreas H (Centre for Clinical Tuberculosis Research, Department of Science and Technology and National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa) ,  Dawson Rodney (Centre for Tuberculosis Research Innovation, University of Cape Town, Grote Schuur, South Africa) ,  Rehal Sunita (MRC Clinical Trials Unit at UCL, London, UK) ,  Kibiki Gibson S (Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Tumaini University, Moshi, Tanzania) ,  Churchyard Gavin (Aurum Institute, Johannesburg, South Africa) ,  Churchyard Gavin (School of Public Health, University of Witwatersrand, Johannesburg, South Africa) ,  Churchyard Gavin (Department of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK) ,  Sanne Ian (Helen Joseph Hospital, Johannesburg, South Africa) ,  Ntinginya Nyanda E (National Institute for Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania) ,  Minja Lilian T (Ifakara Health Institute, Bagamoyo, Tanzania) ,  Hunt Robert D (Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, UK) ,  Charalambous Salome (Aurum Institute, Johannesburg, South Africa) ,  Hanekom Madeleine (Centre for Clinical Tuberculosis Research, Department of Science and Technology and National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Health Sciences, University of Stellenbosch, Tygerberg, South Africa) ,  Semvua Hadija H (Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Tumaini University, Moshi, Tanzania) ,  Mpagama Stellah G (Kibong’oto National Tuberculosis Hospital, Tanzania) ,  Manyama Christina (National Institute for Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania) ,  Mtafya Bariki (National Institute for Medical Research, Mbeya Medical Research Centre, Mbeya, Tanzania) ,  Reither Klaus (Swiss Tropical and Public Health Institute, Basel, Switzerland) ,  Reither Klaus (University of Basel, Basel, Switzerland) ,  Wallis Robert S (Aurum Institute, Johannesburg, South Africa) ,  Venter Amour (MRC Centre for Tuberculosis Research, University of Stellenbosch, Tygerberg, South Africa) ,  Narunsky Kim (Centre for Tuberculosis Research Innovation, University of Cape Town, Grote Schuur, South Africa) ,  Mekota Anka (Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany) ,  Henne Sonja (Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany) ,  Colbers Angela (Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands) ,  van Balen Georgette Plemper (Department of Lung Diseases, Radboud University Medical Center, Nijmegen, Netherlands) ,  Gillespie Stephen H (Medical School University of St Andrews, North Haugh, St Andrews, UK) ,  Phillips Patrick P J (MRC Clinical Trials Unit at UCL, London, UK) ,  Hoelscher Michael (Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich, Munich, Germany) ,  Hoelscher Michael (German Center for Infection Research, Partner Site Munich, Germany)
Material： Lancet Infectious Diseases
Volume： 17  Issue： 1  Page： 39-49  Publication year： 2017 
JST Material Number： W3107A  ISSN： 1473-3099  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Tuberculosis is the world’s le...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1189579&from=J-GLOBAL&jstjournalNo=W3107A") }}

Thesaurus term： hospital ,  *randomized controlled trial ,  drug therapy ,  *tuberculosis ,  regression model ,  solid medium ,  patient ,  culture(biology) ,  sensitivity ,  recurrence ,  safety ,  phenotype ,  nitrogen heterocyclic compound ,  carboxamide

JST classification (2)： Treatment for infectious diseases,parasitic diseases.  (GD01030D) ,  Clinical application of antibacterial drugs  (GW17030D)

Substance index (3)： Pyrazinamide ,  Isoniazide ,  Moxifloxacin

Terms in the title (7)： 結核 ,  高用量 ,  リファンピシン ,  モキシフロキサシン ,  マルチ ,  段階 ,  無作為化対照試験